Humanigen Treats First Patient in Late-Stage COVID-19 Trial

Shares of Humanigen (HGEN) gained 3.4% on October 30 after it announced that the first patient in its Phase 3 COVID-19 trial had been treated with its lenzilumab drug at the MedStar Washington Hospital Center in Washington, D.C.   MedStar is one of 18 sites in the U.S. approved to enroll eligible patients, and the primary goal of the Phase 3 randomized, double-blind, multicenter, placebo-controlled clinical trial is to investigate if lenzilumab, which was designed to prevent and treat the...